Member Info for potnak

Max. There are a lot of IMM investors who bought at 170p. They are nowhere near breaking even. A 4 bagger for SAR would even see us at 1.6p, the SP we got the after the CHK1 licence was announced in 2016.

The Parker thing is just draining. Tim and John must think he adds value or he wouldn't be there. If you really think Parker is taking the p*ss. What does that say about Tim and John? They are letting him? If so, I'm with ColdFish, they are just as complicit. This is why I only check in here a couple of times a day. The company has told us the plans, we know nothing is going to happen this year or until Sierra pull their finger out so what else is everyone expecting to happen? Clicking refresh every 5 minutes is not going to help, log off for a while, enjoy life and one day, you might just wake up to the mother of all RNS's.

I think it will retrace. Nice bit of action for anyone buying recently though. For LTH IMM were trading at 170p less than 2 years ago. And Yes, Thoth did call it. I remember watching with a morbid fascination, the ramping on the run up to news release followed by the blame game when the SP tanked to just 10% of that in one day. You need big balls to wait for a P3 readout.

Cold fish. What you describe is all we need. We only have to start the trials. just as we did with CHK1.

I'm with Thoth here. I think we'll get our milestone Q1 next year. They will not give it back. Potential is too big for the amount of investment needed. I still think our best option is to use the CHK1 milestone to fund P1 for TYK2 then licence. It will be cutting it fine though. If there are any legs in Aurora, we should sell it on just to tide us over. I know Parker isn't liked here but I would imagine he's looking at all the options.

Probably not an experienced day trader but disciplined nonetheless. The spread has been too big for a start but these things happen when you day trade. I wish I was only £203 down. ha ha

We should get an RNS any day now. probably tomorrow.

I don't think there is anything in this little bit of activity and movement. I am encouraged by it though. 47 trades on nothing could bode well when applied to a stonking RNS.

RMM. I may be completely wrong but I think they will announce the trial and milestones payments for 737. Once the money is in from this latest round of fundraising. If they don't, without a good reason. Then I'm with you. Time for CRT to step in. This is the cutting them slack bit.

ColdFish I agree to some extent but I remember 5 or 6 years ago. We were talking about how we needed CHK1 licencing so we could fund TYK2.

Obelix - they are taking the path of least resistance to the market. At the moment momelotinib is that path. I've got a feeling CRT are cutting them a bit of slack and I also think that Sierra thought CHK1 would be better than it has turned out to be. I don't mean efficacy, i mean in indications. Bit of a paradox but narrowing down the indications to improve the chance of success also turned the market off so as DocCardo was saying. The value of the company is based on momelotinib and CHK1 is a sideshow. This would have happened whoever we licenced with and a big pharma may have pulled the plug on CHK1 before now. I happen to think we will get our milestones in the next few months but just as CHK1 is a sideshow for Sierra, it's also a sideshow for Sareum. TYK2 is and always was the big contender for us.

Hi Krone. Only in the way DonCardo stated the other day. This money is earmarked for Momentum which leaves the current cash pile free to use elsewhere. More than enough to pay milestones and fund the trial for 737. Not saying this is what I'm expecting but it sounds feasible.

Less than 10% of the company though. It's literally pennies to Gilead. Nice profit if SRA737 gets to market.

RMM - it's pretty Obvious that our compounds aren't that great or we don't have enough data to prove they are just yet. As usual, the emotion on this board is driven by expectation rather than what the company tells us. The trading statement back in Aug laid it all out pretty clearly. Who was expecting the 10Q to have provisions for milestones? I wasn't. The first we will hear is when a deal to on licence is struck or the milestones are renegotiated. Not likely to be imminent, IMO. As Thoth says, they would have raised after if they knew it was imminent. So that leaves us with TYK2. I think we will know by the end of the year what the plan is for this. My guess is a small upfront deal for cancer and then more waiting.

Understand the sentiment, ColdFish but do you really want to take 1p? 2p? is that significant value to you. Our board have got to hold their nerve and push TYK2 into trials. Then we can sell for a much higher premium. Maybe we should negotiate with Sierra on milestones? a total £5 million milestone, £1.25 mil for SAR would see us to next Christmas. Easy enough time to get our house in order. I personally haven't come this far for a paltry 30% profit. So I hope the board doesn't share your sentiments.

23 Aug 2019 Klencke, Barbara Chief Level Officer Regular purchase transaction 108,000.00 $0.44 $47,379.60 162,000.00
22 Aug 2019 Klencke, Barbara Chief Level Officer Regular purchase transaction 67,000.00 $0.43 $28,964.10 67,000.00
22 Aug 2019 Klencke, Barbara Chief Level Officer Regular purchase transaction 54,000.00 $0.45 $24,294.60 54,000.00

Hi Stoney - Agreed but we need SRA737 to be as good as they say it is so they can get a deal. If it comes back to us it'll be 6 months 12 months, who knows? we will have to raise just to keep afloat. I still think NG has got something up his sleeve and with SAR's current financial situation, it will be the least risky option. Unless Tim knows something we don't, We might have to raise this year. We'll certainly need to do it it January if no CHK1 or TYK2 news by then. The senior manager buys gives me some hope that there is something in the pipeline.

Wouldn't that be a turn up for the books, Thoth. Seems unlikely but as stated in the article you linked to. It has and does happen. It would explain the silence and lack of panic from Sierra's board!

I don't think we were expecting any milestone news in this Q10, were we? I certainly wasn't. IMO. They have no intention of handing back sra737. Any setback on SRA141 and they are literally finished as a company without 737. NG knows all this and I suspect it was all in the plan when they decided to resuscitate momelotinib. They knew they couldn't fund SRA737 without further investment so, IMO they were hoping that good progress on momelotinib p3 to fill the gap and to keep investors interested. Unfortunately, it has backfired or was it anticipated? For the time being it changes nothing for SAR. Sierra are still aiming for Q4 to launch the P3 trial, they have the funds to do it. I don't see a reason for the timescale to slip. This latest Q10 is just regulatory. They have to put it out so, I agree with RMM, this was prepared and released early to get it out of the way. The company's future depends on securing funding for SRA737 and i'm pretty sure that's where NG's focus will be. and Yes, give us the Lupus news for Christmas please, Tim.

We just need Sierra to sort themselves out. I don't mind waiting for those types of figures. Receiving a nice milestone would derisk us somewhat and the wait would be more pleasant than it is right now.